



[MDCG 2022-4 – Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the MDR](#)



Autoridade Nacional do Medicamento e Produtos de Saúde I.P.

[Uderivados em produtos cosméticostilização de canábis e seus](#)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

[Generating high-quality evidence from registry-based studies](#)

EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Engagement Framework:  
EMA and patients, consumers  
and their organisations**

[EMA's engagement framework with patients, consumers and their organisations](#)

**efpia**

[Shifting the paradigm for ATMPs: Adapting reimbursement and value frameworks to improve patient access in Europe](#)



Autoridade Nacional do Medicamento e Produtos de Saúde I.P.

[Nota técnica “Gestão de Resíduos de Canábis, no âmbito de atividades que produzem canábis para fins medicinais”](#)




EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

[Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines](#)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

[A stronger role for EMA](#)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

[New EU rules for safe and high-quality medicines for animals become effective](#)



[Publicação de alteração ao Regulamento \(UE\) 2017/746 relativo aos dispositivos para diagnóstico in vitro](#)



innovativ  
medicine  
initiativ

[Innovative Health Initiative](#)